3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
32
Neoplasms
19
Neoplasm Metastasis
5
Brain Neoplasms
3
Thyroid Neoplasms
2
Thyroid Cancer, Papillary
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid Carcinoma, Anaplastic
1
Skin Neoplasms
1
Sarcoma
1
Oligodendroglioma
1
Nonseminomatous germ cell tumor
1
Neurofibroma, Plexiform
1
Neurocytoma
1
Neuroblastoma
1
Multiple Myeloma
1
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
1
Leukemia, Hairy Cell
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Ganglioneuroma
1
Ganglioglioma
1
Fever
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pegfilgrastim
3
liposomal amphotericin B
2
Vancomycin
2
Filgrastim
2
Caspofungin
2
trametinib
1
ofatumumab
1
dabrafenib
1
Teicoplanin
1
Tazobactam
1
Surveys and Questionnaires
1
Ritonavir
1
Quality of Life
1
Povidone-Iodine
1
Piperacillin, Tazobactam Drug Combination
1
Piperacillin
1
Metformin
1
Meropenem
1
Lenalidomide
1
Itraconazole
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Granulocyte Colony-Stimulating Factor
1
Doxorubicin
1
Docetaxel
1
Daptomycin
1
Cyclophosphamide
1
Cloxacillin
1
Cilastatin, Imipenem Drug Combination
1
Ceftazidime
1
Cefepime
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Fever
×
dabrafenib
×
Clear all
NCT03551626
2025-04-29
COMBI-APlus
Novartis
Phase 3
Completed
552 enrolled
12 charts